Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer

Carcinogenesis

Volumn 35, Issue 4, 2014, Pages 905-914

  Liu, Zi ^a,b   Ma, Liang ^a   Wen, Zhe Sheng ^c   Hu, Zheng ^d   Wu, Fu Qun ^e   Li, Wei ^a   Liu, Jinsong ^d   Zhou, Guang Biao ^a  

^a INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; CARBOXYL TERMINUS OF HEAT SHOCK PROTEIN 70 INTERACTING PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; CELASTROL; CISPLATIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEASOME; PROTEIN KINASE B; UBIQUITIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRIPTERYGIUM WILFORDII;

ANIMALS; AUTOANTIGENS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; PROTEOLYSIS; TRITERPENES; TUMOR MARKERS, BIOLOGICAL; UBIQUITINATION;

EID: 84894042781     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt395     Document Type: Article

References (53)

1. Govindan, R. et al. (2012) Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell, 150, 1121-1134.
2. Esteller, M. (2008) Epigenetics in cancer. N. Engl. J. Med., 358, 1148-1159.
3. Paez, J.G. et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-1500.
4. Herbst, R.S. et al. (2008) Lung cancer. N. Engl. J. Med., 359, 1367-1380.
5. Hoo, L.S. et al. (2002) Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene, 21, 5006-5015.
6. Chen, K.F. et al. (2010) CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene, 29, 6257-6266.
7. Ma, L. et al. (2011) Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. Plos One, 6, e20159.
8. Junttila, M.R. et al. (2007) CIP2A inhibits PP2A in human malignancies. Cell, 130, 51-62.
9. Côme, C. et al. (2009) CIP2A is associated with human breast cancer aggressivity. Clin. Cancer Res., 15, 5092-5100.
10. Khanna, A. et al. (2009) MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J. Natl Cancer Inst., 101, 793-805.
11. Dong, Q.Z. et al. (2011) CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann. Surg. Oncol., 18, 857-865.
12. Böckelman, C. et al. (2011) Prognostic role of CIP2A expression in serous ovarian cancer. Br. J. Cancer, 105, 989-995.
13. Lucas, C.M. et al. (2011) Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood, 117, 6660-6668.
14. Laine, A. et al. (2013) Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov., 3, 182-197.
15. Choi, Y.A. et al. (2011) Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett., 585, 755-760.
16. Khanna, A. et al. (2011) ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One, 6, e17979.
17. Mathiasen, D.P. et al. (2012) Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene, 31, 390-401.
18. Liu, Y. et al. (2011) Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma. Plos One, 6, e21930.
19. Liu, Y.Q. et al. (2012) Identification of an annonaceous acetogenin mimetic, AA005, as an AMPK activator and autophagy inducer in colon cancer cells. PLoS One, 7, e47049.
20. Yu, X.J. et al. (2012) Gambogenic acid induces G1 arrest via GSK3ß-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells. Cancer Lett., 322, 185-194.
21. Zhen, T. et al. (2012) Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci. Transl. Med., 4, 127ra38.
22. Zhou, G.B. et al. (2007) Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood, 109, 3441-3450.
23. Zhou, G.S. et al. (2011) Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells. Leuk. Res., 35, 214-218.
24. Corson, T.W. et al. (2007) Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell, 130, 769-774.
25. Hu, Z. et al. (2009) Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS One, 4, e6257.
26. Esser, C. et al. (2005) The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J. Biol. Chem., 280, 27443-27448.
27. Harwood, S.M. et al. (2005) Caspase and calpain function in cell death: bridging the gap between apoptosis and necrosis. Ann. Clin. Biochem., 42(Pt 6), 415-431.
28. Ciechanover, A. (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol., 6, 79-87.
29. Adams, J. (2004) The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer, 4, 349-360.
30. Johnston, J.A. et al. (1998) Aggresomes: a cellular response to misfolded proteins. J. Cell Biol., 143, 1883-1898.
31. Sha, Y. et al. (2009) A critical role for CHIP in the aggresome pathway. Mol. Cell. Biol., 29, 116-128.
32. Ballinger, C.A. et al. (1999) Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol., 19, 4535-4545.
33. Sreeramulu, S. et al. (2009) Molecular mechanism of inhibition of the human protein complex Hsp90-Cdc37, a kinome chaperone-cochaperone, by triterpene celastrol. Angew. Chem. Int. Ed. Engl., 48, 5853-5855.
34. Trott, A. et al. (2008) Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol. Biol. Cell, 19, 1104-1112.
35. Morota, T. et al. (1995) D-a-Friedo-24-Noroleanane triterpenoids from Tripterigium-Wilfordii. Phytochemistry, 39, 1159-1163.
36. Klaic, L. et al. (2012) Celastrol analogues as inducers of the heat shock response. Design and synthesis of affinity probes for the identification of protein targets. ACS Chem. Biol., 7, 928-937.
37. Cohen, M.S. et al. (2005) Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science, 308, 1318-1321.
38. Usui, T. et al. (2004) The anticancer natural product pironetin selectively targets Lys352 of alpha-tubulin. Chem. Biol., 11, 799-806.
39. David, O. et al. (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin. Cancer Res., 10, 6865-6871.
40. Brognard, J. et al. (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res., 61, 3986-3997.
41. Chen, C. et al. (2006) Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer. Mol. Cancer Res., 4, 695-707.
42. Yang, H. et al. (2006) Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res., 66, 4758-4765.
43. Hieronymus, H. et al. (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell, 10, 321-330.
44. Mu, T.W. et al. (2008) Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell, 134, 769-781.
45. Chapelsky, S. et al. (2008) Inhibition of anthrax lethal toxin-induced cytolysis of RAW264.7 cells by celastrol. PLoS One, 3, e1421.
46. Lindsten, K. et al. (2003) A transgenic mouse model of the ubiquitin/proteasome system. Nat. Biotechnol., 21, 897-902.
47. Abbas, S. et al. (2007) Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin. Cancer Res., 13(22 Pt 1), 6769-6778.
48. Huang, Y. et al. (2008) Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett., 264, 101-106.
49. Liu, Z. et al. (2011) The main anticancer bullets of the Chinese medicinal herb, thunder god vine. Molecules, 16, 5283-5297.
50. Salminen, A. et al. (2010) Celastrol: molecular targets of Thunder God Vine. Biochem. Biophys. Res. Commun., 394, 439-442.
51. Pang, X. et al. (2010) Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res., 70, 1951-1959.
52. Kannaiyan, R. et al. (2011) Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3K/Akt signaling pathways. Apoptosis, 16, 1028-1041.
53. Liu, L.Z. et al. (2007) AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res., 67, 6325-6332.